Jana Koptíková

Complex karyotypes in childhood acute lymphoblastic leukemia: cytogenetic and molecular cytogenetic study of 21 cases.

Cytogenetic and molecular cytogenetic analysis of 79 childhood acute lymphoblastic leukemias (ALL) revealed chromosomal abnormalities in 76 (96%). Complex karyotypes (a finding of three and more chromosomal aberrations in a karyotype) were identified in 21 (26.6%) out of 79 patients. In 11 patients, complex karyotypes have included common recurrent chromosomal abnormalities, such as translocation t(12;21) in seven cases, t(9;22) in two cases, one case with t(2;1;19) and another one with translocation involving 11q23. In 10 patients, miscellaneous abnormalities were detected. Five patients displayed hyperdiploidy (47 approximately 57 chromosomes), three patients complex karyotypes with deletions of 9p, one patient with two new complex translocations t(2;4;12;13) and t(7;11;20), and the last patient with dic(12;21). The evaluation of the frequency of the chromosomal breaks (>5 per chromosome) showed that chromosomes 2, 4, 5, 7, 9, 12, 13, and 21 were most frequently affected. Survival analysis revealed statistically significant unfavorable event-free survival (EFS) (P=0.013) and decreased overall survival in the group with complex karyotypes (n=21) compared with the other cases (n=58). The evaluation of overexpression profile revealed increased occurrence of double CD13/CD33 positivity in patients with common recurrent chromosomal abnormalities (in 70% of cases); no such cases were registered in the other group (P<0.01).

Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry

BackgroundColorectal cancer (CRC) represents a serious health care problem in the Czech Republic, introducing a need for a prospective modelling of the incidence and prevalence rates. The prevalence of patients requiring anti-tumour therapy is also of great importance, as it is directly associated with planning of health care resources.MethodsThis work proposes a population-based model for the estimation of stage-specific prevalence of CRC patients who will require active anti-tumour therapy in a given year. Its applicability is documented on records of the Czech National Cancer Registry (CNCR), which is used to estimate the number of patients potentially treated with anti-tumour therapy in the Czech Republic in 2015.ResultsSeveral scenarios are adopted to cover the plausible development of the incidence and survival rates, and the probability of an anti-tumour therapy initiation. Based on the scenarios, the model predicts an increase in CRC prevalence from 13% to 30% in comparison with the situation in 2008. Moreover, the model predicts that 10,074 to 11,440 CRC patients will be indicated for anti-tumour therapy in the Czech Republic in 2015. Considering all patients with terminal cancer recurrence and all patients primarily diagnosed in stage IV, it is predicted that 3,485 to 4,469 CRC patients will be treated for the metastatic disease in 2015, which accounts for more than one third (34-40%) of all CRC patients treated this year.ConclusionsA new model for the estimation of the number of CRC patients requiring active anti-tumour therapy is proposed in this paper. The model respects the clinical stage as the primary stratification factor and utilizes solely the population-based cancer registry data. Thus, no specific hospital data records are needed in the proposed approach. Regarding the short-term prediction of the CRC burden in the Czech Republic, the model confirms a continuous increase in the burden that must be accounted for in the future planning of health care in the Czech Republic.

PCN160 MODELLING NUMBER OF CANCER PATIENTS POTENTIALLY TREATED WITH TARGETED PHARMACOTHERAPY IN THE CZECH REPUBLIC

other countries. RESULTS: In terms of price cuts, the new PPRS is a continuation of previous schemes encompassing a 6–7% reduction. Price modulation and profit controls remained unchanged. However, flexible pricing, which encourages companies to initially set lower prices to gain approval and increases prices as more evidence of effectiveness emerges, has been introduced. The most important difference concerns the introduction of PASs, which build on the idea of risk-sharing. Velcade and Lucentis provide useful examples of different approaches: the former defining risk in terms of “patient response” (outcomes-based) and the latter according to treatment utilisation (financial-based). Both schemes continue to be active. CONCLUSIONS: The new PPRS signifies an important shift in the UK policy framework. The introduction of PASs raises issues about scheme implementation and how risk should be measured and tracked overtime. The progress of this initiative will shape the renegotiation of the next PPRS and the setting of future priorities. However, it is likely that “value-based pricing”—however defined and understood—will continue to gain momentum.

P-55 Chemotherapy with ifosfamide and concomitant radiotherapy in limited disease (LD) small cell lung cancer (SCLC)

A restrospective study of 115 consecutive pts. with limited SCLC was aimed at therapeutic results and toxicity. From preliminary results authors conclude that the use of IFO/CBDCA/VP16 with concomitant raditherapy is an effective therapy, radiotherapy reducing the treatment time.

P-703 A realistic view of the surgical treatment in patients with non-small cell lung cancer (NSCLC): An analysis of 248 patients

248 patients with primary NSCL were analyzed; 29% of them underwent radical resection. The results so far show a better survival for pts. with radical resection compared with pts. with neoadjuvant therapy, but the study is sill in progress.